ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.32 0.37 (2.32%) Market Cap: 2.71 Bil Enterprise Value: 2.20 Bil PE Ratio: 90.67 PB Ratio: 5.23 GF Score: 74/100

Q2 2023 ACADIA Pharmaceuticals Inc Earnings Call Transcript

Aug 02, 2023 / 08:30PM GMT
Release Date Price: $29.2 (+0.90%)
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. My name is (inaudible), and I will be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Jessica Tieszen, Associate Director of Investor Relations at ACADIA. Please proceed.

Jessica Tieszen

Thank you. Good afternoon and thank you for joining us on today's call to discuss ACADIA's second quarter 2023 earnings. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide some opening remarks; followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss the DAYBUE launch and NUPLAZID execution. Doug Williamson, our Head of Research and Development, will provide an update on our pipeline programs; and Mark Schneyer, our Chief Financial Officer, will review the financial highlights. Steve will then provide some closing thoughts before we open the call up for your questions. In addition, Kathie Bishop, our Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot